ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / SCLX / dividends
PLUR (33) DYAI (31) BCDA (38) JSPR (37) ⌘ Pro Terminal β†’

Scilex Holding Company (SCLX) Dividend Safety Gauge & 10-Year DRIP Compounder

$1.85 -10.19% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.81

Scilex Holding Company (SCLX) carries a Roarable Rating of D- (Sell) with 40/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record Warning: Scores below 50 (40/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows β†’
ROARABLE D- β€’ RED ALERT Cap $15.7M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SCLX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #538 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does SCLX compare to PLUR and DYAI in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and DYAI (Dyadic International Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SCLX?
β–Ό

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.81 (-2.02%)🧬 Disciplined Float (-0.40% YoY Shares)βš™οΈ Cash Engine: 12/20 (C-) β€’ 12.2% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (40/100 Β· D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ D-
025507510040
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- Β· Rk D-
Cash (12)Whales (3)SEC (8)Macro (8)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-8.1% Base Target
$18 Bull$2 Base$1 Bear
πŸ“¬ FREE SCLX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for SCLX)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (40/100 Composite)
πŸ” WHY SCLX SCORES 40/100 (D-) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Cash Engine Quality+12/20 pts (30% of score)

SEC XBRL FY 2025 (10-K): 12.2% FCF Margin ($3.7M FCF) & 415.8% Gross Margin

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+9/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 45% Net Buy β€’ Disciplined Float (-0.40% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
48
Grade D$2.88-12.2% Next Q
Q2 (-2Q)
45
Grade D$2.53-19% Next Q
Q3 (-1Q)
43
Grade D$2.05-9.8% Next Q
Current
40
Grade D-$1.85-7.4% Hist 90D Ξ±
Trajectory: D (48) β†’ D- (40)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a SCLX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While SCLX currently carries a cautious 40/100 (D-) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.02) and Max Pain ($1.94) forces dealer call-delta covering toward $17.65.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SCLXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œSCLX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 40%NO 60%Trade / Inspect Odds β†’
CASH DIVIDEND + BUYBACK YIELD
1.8% Total Yield
0% Cash ($0.00/yr) + 1.8% Buybacks
PAYOUT SAFETY SPEEDOMETER
74/100 β€’ REINVESTING IN GROWTH + BUYBACKS
FREE CASH FLOW PAYOUT RATIO
0% (100% Reinvested)
Retains cash flow for R&D and share repurchases
INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years β†’ $17,081

Est. Year-10 Shareholder Yield: $307/yr
$10.6K
Yr 1
$11.1K
Yr 2
$11.7K
Yr 3
$12.4K
Yr 4
$13.1K
Yr 5
$13.8K
Yr 6
$14.5K
Yr 7
$15.3K
Yr 8
$16.2K
Yr 9
$17.1K
Yr 10
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SCLX)

  • βœ“Walkthrough of SCLX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
SCLX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -73.34%πŸ›‘οΈ HOLDING TREND SUPPORT
2026-11-03O $2.06H $2.06L $1.85C $1.85VOL 49.9K
RES: $8.73SUP: $1.69SMA50: $4.02SMA200: $5.26
$11.03$8.54$6.04$3.55$1.06RES $8.73SUP $1.69$1.852026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SCLX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ SCLX Butterfly Map β†’ + Track SCLX β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -46.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SCLX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for SCLX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SCLX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SCLX)

Health Care Rank #538 of 1016 βš”οΈ PLUR vs SCLX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (SCLX vs. PLUR, DYAI, BCDA, JSPR)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Scilex Holding Company (SCLX) ranks #538 by composite RQD confidence (40/100, grade D-) and #842 by equity capitalization ($15.7M). Within this direct 5-issuer industry benchmark cohort, SCLX leads on earnings valuation at N/A trailing P/E, while SCLX leads on capital efficiency and profitability with -35.0% ROIC and 96.0% gross margin. SCLX currently leads its immediate peer cohort in composite quantitative strength at 40/100 (D-).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
SCLX ACTIVE
Scilex Holding Company
D- 40/100 β€” 96.0% -35.0% -10.19% $15.7M Benchmark Subject
PLUR
Pluri Inc.
E 33/100 β€” 49.0% -35.0% +3.33% $16.1M /plur-vs-sclx β†’
DYAI
Dyadic International Inc.
E 31/100 β€” 24.9% -35.0% +5.32% $14.5M /dyai-vs-sclx β†’
BCDA
BioCardia Inc.
D- 38/100 β€” β€” -35.0% -7.02% $14.0M /bcda-vs-sclx β†’
JSPR
Jasper Therapeutics Inc.
D- 37/100 β€” β€” -35.0% -2.22% $17.7M /jspr-vs-sclx β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001820190

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Scilex Holding Company (SCLX) reported GAAP revenue of $30.3M (-46.5% vs. FY2024 revenue of $56.6M , and -35.3% cumulative change since FY2023) , GAAP net income of -$374.1M, operating cash flow of $3.8M, and free cash flow of $3.7M (-81.0% YoY). On the balance sheet, SCLX closed FY2025 with $365.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $30.3M -$374.1M $3.8M $3.7M $365.0M β€”
FY2024 (FY) 2024-12-31 $56.6M -$72.8M $19.3M $19.3M $93.0M β€”
FY2023 (FY) 2023-12-31 $46.7M -$114.3M -$20.7M -$20.7M β€” β€”

3. SCLX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SCLX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Scilex Holding Company (NASDAQ: SCLX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 40/100 at a spot price of $1.85 (-10.19% 1D, market cap $15.7M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, SCLX ranks #538 in composite RQD confidence.

How does SCLX compare to PLUR and DYAI in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), SCLX carries a Roarable D- (40/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, PLUR (Pluri Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $16.1M) and DYAI (Dyadic International Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $14.5M). Among the 5-stock peer group, SCLX leads on earnings multiple (N/A) while SCLX leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SCLX?

Per SCLX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001820190), Scilex Holding Company generated $30.3M in revenue (-46.5% YoY), -$374.1M in net income, and $3.7M in free cash flow against $365.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SCLX trading relative to its 50-day, 200-day, and 52-week technical levels?

SCLX last traded at $1.85 (-10.19% on volume of 49,895 shares), positioning the stock -53.98% below its 50-day simple moving average ($4.02) and -64.83% below its 200-day simple moving average ($5.26). Across its 52-week range of $1.83 to $16.81, SCLX sits at the 0.1% percentile with a 14-day RSI of 20.9 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($1.62 to $2.08).

SCLX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Does SCLX pay a dividend and is it safe?

Scilex Holding Company (SCLX) offers a 0% cash dividend yield ($0.00 annualized) and 1.8% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: SCLX RQD Cockpit SCLX 12M Forecast SCLX Earnings & Move SCLX Dividends & DRIP SCLX Insiders & 13F SCLX Whale Options SCLX Profit Sankey SCLX News & Why
ROARABLE RATING BRIEF β€’ RQD 40/100 (D-) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

SCLX β€” Scilex Holding Company: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:50:14Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, SCLX carries an RQD Score of 40, a letter grade of D-, and the verdict label "Roarable Sell β€” Vulnerable Balance Sheet & Flow." The five pillars are scored as follows:

  • Fundamental Cash Engine: 12 / 20. The pillar notes ROIC of -35% alongside an FCF yield of 21.05%. For a prospective investor, the strong FCF yield sits against a deeply negative return on invested capital, so the cash signal and the profitability signal point in different directions and require closer scrutiny before any conclusion is drawn.
  • Whale 13F Flow: 3 / 20. This is the weakest pillar and is described as covering institutional accumulation and options positioning. A low score here indicates that the institutional-flow signal provides little support for the stock.
  • Insider Conviction: 9 / 20. This pillar covers SEC Form 4 and Congressional PTR cluster flow. A below-midpoint score suggests insider and disclosed-trade activity offers limited conviction support.
  • Macro Regime Fit: 8 / 20. The pillar references a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity, while the score indicates the macro-regime backdrop is not favorable to the name.
  • Forensic Balance Sheet: 8 / 20. The pillar cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity ratio of 0.5. These readings fall in a middle-to-weak range, and the balance-sheet score signals vulnerability rather than strength.

Taken together, the pillars indicate that the valuation discount (price of $2.06 against a 52-week range of $1.83–$16.81) reflects a deteriorated fundamental and flow picture rather than a clear mispricing. Upside drivers would need to come from a reversal in operating losses or a shift in institutional and insider positioning, neither of which is evidenced in the source data. The rating framework therefore frames SCLX as a high-risk profile where the downside factors currently outweigh the supportive ones.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025 (filed 2025-12-31)$30.3M$-346.0M$-374.1MN/A$3.7M$5.0MN/A
FY 2024 (filed 2024-12-31)$56.6M$-83.4M$-72.8MN/A$19.3M$3.3MN/A
FY 2023 (filed 2023-12-31)$46.7M$-105.4M$-114.3MN/A$-20.7MN/AN/A

Per the SEC financials, revenue declined from $56.6M in FY 2024 to $30.3M in FY 2025, while net loss widened to $-374.1M. Per the market data, net margin is -60% and ROIC is -35%. Per the Roarable RQD rating, the forensic pillar cites an Altman Z of 2.5, a Piotroski F of 4/9, and a Debt/Equity ratio of 0.5, which together describe a balance sheet with limited financial strength. Reported cash of $5.0M against a net loss of $-374.1M highlights liquidity sensitivity in the source data.

Open Questions

  • What drove the revenue decline from $56.6M in FY 2024 to $30.3M in FY 2025, and what products or segments were affected?
  • What explains the $-374.1M net loss in FY 2025 relative to the $-72.8M loss in FY 2024?
  • What is the company's total debt, since the debt field is reported as N/A across all periods?
  • What is the source of the discrepancy between the rounded $0.0B market-cap label in the profile and the $17.5M market-cap figure in the market data?
  • What is the company's EPS and debt position given that EPS is reported as N/A across all periods?

SCLX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Scilex Holding Company (SCLX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to SCLX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SCLX Bull vs. Bear Conversation Board β€” What's Your Call at $1.85?

πŸ‚ 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SCLX 🐻 67% BEARISH CONVICTION
1. Pick Your Side on SCLX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH 🎯 Target: $1.81 (-12.1%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is SCLX (D- β€’ RQD 40/100) a Buy at $2.06?

Welcome to the SCLX (Scilex Holding Company) Roar Pit. Current RQD Composite is 40/100 (Roarable Sell β€” Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $1.59 (-22.8%)
Spot @ $2.06

Pump the brakes on SCLX β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on SCLX, but look at what you are paying: current EV/EBITDA multiples with 96.0% gross margins. Unless Scilex Holding Company expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

TA TapeReader_Pro Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $2.49 (+20.9%)
Spot @ $2.06

SCLX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on SCLX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.06 (52-wk range $1.83 - $16.81), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%